The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group
Abstract
Purpose: Retroperitoneal lymph node dissection (RPLND) and adjuvant chemotherapy are two adjuvant treatment options for patients with clinical stage I nonseminomatous germ cell tumors of the testis (NSGCT). Aim of this trial was to prove the advantage of one cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy compared with RPLND in terms of recurrence. Patients and Methods: Between 1996 and 2005, 382 patients were randomly assigned to receive either RPLND (n = 191) or one course of BEP (n = 191) after orchidectomy. The primary study end point was the rate of recurrence. The trial was powered to detect a 7% reduction (from 10% to 3%) of recurrence with chemotherapy compared with surgery. Results: After a median follow-up of 4.7 years, two and 15 recurrences were observed in the intention-to-treat population with chemotherapy and surgery, respectively (P = .0011). The difference in the 2-year recurrence-free survival rate between chemotherapy (99.46%; 95% CI, 96.20% to 99.92%) and surgery (91.87%; 95% CI, 86.87% to 95.02%) was 7.59% (95% CI, 3.13% to 12.05%). The hazard ratio to experience a tumor recurrence with surgery as opposed to chemotherapy was 7.937 (95% CI, 1.808 to 34.48). Conclusion: To our knowledge, this is the largest randomized trial investigating adjuvant treatment strategies in clinical stage I NSGCT, which showed the superiority of one course BEP over RPLND performed according to community standards to prevent recurrence. Although not standard treatment, one course of BEP is active in an unselected group of patients with clinical stage I disease and merits further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
Travis, L. B., Fosså, S. D., Schonfeld, S. J., McMaster, M. L., Lynch, C. F., Storm, H., Hall, P., Holowaty, E., Andersen, A., Pukkala, E., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji278 · Cited by 823
Bleyer, A., O’Leary, M., Barr, R. D., & Ries, L. A. G. (2006) · Cited by 619
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., & Dearnaley, D. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.173 · Cited by 547
Schmoll, H. J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S. D., Skakkebaek, N. E., de Wit, R., Fizazi, K., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh301 · Cited by 510
Self-citationEvaluation of long-term toxicity after chemotherapy for testicular cancer.
Bokemeyer, C., Berger, C. C., Kuczyk, M. A., & Schmoll, H. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2923 · Cited by 268
Study of anxiety disorder and depression in long-term survivors of testicular cancer
Dahl, A. A., Haaland, C. F., Mykletun, A., Bremnes, R., Dahl, O., Klepp, O., Wist, E., & Fosså, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.061 · Cited by 176
Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review
Vergouwe, Y., Steyerberg, E. W., Eijkemans, M. J. C., Albers, P., & Habbema, J. D. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.094 · Cited by 165
Self-citationOliver, R. T. D., Ong, J., Shamash, J., Ravi, R., Nagund, V., Harper, P., Ostrowski, M. J., Sizer, B., LeVay, J. H., Robinson, A. C. R., et al. (2004) · Urology · doi:10.1016/j.urology.2003.10.023 · Cited by 100
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Self-citationTesticular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy217 · Cited by 326
Self-citation
Metadata
- Authors
- Albers, P., Siener, R., Krege, S., Schmelz, H.-U., Dieckmann, K.-P., Heidenreich, A., Kwasny, P., Pechoel, M., Lehmann, J., Kliesch, S., Köhrmann, K.-U., Fimmers, R., Weiβbach, L., Loy, V., Wittekind, C., & Hartmann, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-06-20
- Volume
- 26
- Issue
- 18
- Pages
- 2966-2972
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141964341
- Cited by
- 337
- References
- 8
- FWCI
- 20.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. https://app.cochat.ai/papers/10.1200/jco.2007.12.0899
- The paper
- Albers, P., Siener, R., Krege, S., Schmelz, H.-U., Dieckmann, K.-P., Heidenreich, A., Kwasny, P., Pechoel, M., Lehmann, J., Kliesch, S., Köhrmann, K.-U., Fimmers, R., Weiβbach, L., Loy, V., Wittekind, C., & Hartmann, M. (2008). Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.12.0899
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.